

Peter J Boström

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8927057/publications.pdf>

Version: 2024-02-01

151
papers

4,097
citations

109137

35
h-index

149479

56
g-index

154
all docs

154
docs citations

154
times ranked

5885
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and efficacy of MRI-guided transurethral ultrasound ablation for radiorecurrent prostate cancer in the presence of gold fiducial markers. <i>Acta Radiologica</i> , 2023, 64, 1228-1237.	0.5	3
2	Magnetic resonance imaging-guided transurethral ultrasound ablation for benign prostatic hyperplasia: 12-month clinical outcomes of a phase I study. <i>BJU International</i> , 2022, 129, 208-216.	1.3	9
3	Detection of Prostate Cancer Using Biparametric Prostate ^{sc}MRI</sup>, Radiomics, and Kallikreins: A Retrospective Multicenter Study of Men With a Clinical Suspicion of Prostate Cancer. <i>Journal of Magnetic Resonance Imaging</i> , 2022, 55, 465-477.	1.9	9
4	Incidence of and mortality from Bacille Calmette-Guérin (BCG) infections after BCG instillation therapy. <i>BJU International</i> , 2022, 129, 737-743.	1.3	5
5	Increased Expression and Altered Cellular Localization of Fibroblast Growth Factor Receptor-Like 1 (FGFR1) Are Associated with Prostate Cancer Progression. <i>Cancers</i> , 2022, 14, 278.	1.7	2
6	The variant rs77559646 associated with aggressive prostate cancer disrupts <i>ANO7</i> mRNA splicing and protein expression. <i>Human Molecular Genetics</i> , 2022, 31, 2063-2077.	1.4	7
7	Awareness of Smoking as a Risk Factor in Bladder Cancer: Results from the Prospective FinnBladder 9 Trial. <i>European Urology Focus</i> , 2022, 8, 1246-1252.	1.6	6
8	Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 110.e1-110.e9.	0.8	22
9	Uptake of ¹⁸F-rhPSMA-7.3 in Positron Emission Tomography Imaging of Prostate Cancer: A Phase 1 Proof-of-Concept Study. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2022, 37, 205-213.	0.7	3
10	Individualised non-contrast MRI-based risk estimation and shared decision-making in men with a suspicion of prostate cancer: protocol for multicentre randomised controlled trial (multi-IMPROD) <i>Tj ETQq0 0 0 rgBT. #Overlock 10 Tf 50</i>		
11	Mortality after surgery for benign prostate hyperplasia: a nationwide cohort study. <i>World Journal of Urology</i> , 2022, , 1.	1.2	0
12	Randomised double-blind phase 3 clinical study testing impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy: study protocol. <i>BMJ Open</i> , 2022, 12, e050264.	0.8	5
13	Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD). <i>European Urology Oncology</i> , 2021, 4, 971-979.	2.6	56
14	A Prospective Comparison of 18F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Traditional Imaging in Primary Distant Metastasis Staging of Prostate Cancer (PROSTAGE). <i>European Urology Oncology</i> , 2021, 4, 635-644.	2.6	58
15	Test-retest repeatability of a deep learning architecture in detecting and segmenting clinically significant prostate cancer on apparent diffusion coefficient (ADC) maps. <i>European Radiology</i> , 2021, 31, 379-391.	2.3	15
16	Long-term Surveillance of Patients with Complete Response Following Chemotherapy for Metastatic Nonseminomatous Germ Cell Tumor. <i>European Urology Oncology</i> , 2021, 4, 289-296.	2.6	13
17	Which data are available in central registries on bladder cancer patients in the five Nordic countries. <i>Scandinavian Journal of Urology</i> , 2021, 55, 135-141.	0.6	0
18	Prospective comparison of 18F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2951-2959.	3.3	26

#	ARTICLE	IF	CITATIONS
19	A three-feature prediction model for metastasis-free survival after surgery of localized clear cell renal cell carcinoma. <i>Scientific Reports</i> , 2021, 11, 8650.	1.6	10
20	Kinetic analysis and optimisation of 18F-rhPSMA-7.3 PET imaging of prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3723-3731.	3.3	10
21	Negative Predictive Value of Biparametric Prostate Magnetic Resonance Imaging in Excluding Significant Prostate Cancer: A Pooled Data Analysis Based on Clinical Data from Four Prospective, Registered Studies. <i>European Urology Focus</i> , 2021, 7, 522-531.	1.6	10
22	Computer extracted gland features from H&E predicts prostate cancer recurrence comparably to a genomic companion diagnostic test: a large multi-site study. <i>Npj Precision Oncology</i> , 2021, 5, 35.	2.3	13
23	Response to the Letter to the Editor: Prospective comparison of 18F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2672-2673.	3.3	2
24	Prognostic and predictive value of ALDH1, SOX2 and SSEA-4 in bladder cancer. <i>Scientific Reports</i> , 2021, 11, 13684.	1.6	3
25	Risk factors associated with positive surgical margins location at radical cystectomy and their impact on bladder cancer survival. <i>World Journal of Urology</i> , 2021, 39, 4363-4371.	1.2	22
26	Visual MRI T-category versus VI-RADS evaluation from multiparametric MRI in the detection of muscle-invasion in patients with suspected bladder cancer: single centre registered clinical trial (MIB-trial). <i>Scandinavian Journal of Urology</i> , 2021, 55, 354-360.	0.6	5
27	How to read biparametric MRI in men with a clinical suspicion of prostate cancer: Pictorial review for beginners with public access to imaging, clinical and histopathological database. <i>Acta Radiologica Open</i> , 2021, 10, 205846012110607.	0.3	1
28	Fiducial markers and their impact on ablation outcome for patients treated with MR-guided transurethral ablation (TULSA): a retrospective technical analysis. <i>International Journal of Hyperthermia</i> , 2021, 38, 1677-1684.	1.1	1
29	Symptoms and diagnostic delays in bladder cancer with high risk of recurrence: results from a prospective FinnBladder 9 trial. <i>World Journal of Urology</i> , 2020, 38, 1001-1007.	1.2	9
30	Decreased forced expiratory volume in first second is associated with erectile dysfunction in apparently healthy men. A preliminary study.. <i>International Journal of Impotence Research</i> , 2020, 32, 420-425.	1.0	2
31	Repeatability of radiomics and machine learning for DWI: Short-term repeatability study of 112 patients with prostate cancer. <i>Magnetic Resonance in Medicine</i> , 2020, 83, 2293-2309.	1.9	23
32	Reply to Xuefeng Liu's Letter to the Editor, re: Kimmo Kettunen, Peter J. Boström, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. <i>Eur Urol</i> 2019;76:430-4: Can Patient-derived Cancer Models Change the Costliest Cancer Type?. <i>European Urology</i> , 2020, 77, e23.	0.9	2
33	Prostate Cancer Risk Stratification in Men With a Clinical Suspicion of Prostate Cancer Using a Unique Biparametric MRI and Expression of 11 Genes in Apparently Benign Tissue: Evaluation Using Machine Learning Techniques. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 51, 1540-1553.	1.9	3
34	Prebiopsy IMPROD Biparametric Magnetic Resonance Imaging Combined with Prostate-Specific Antigen Density in the Diagnosis of Prostate Cancer: An External Validation Study. <i>European Urology Oncology</i> , 2020, 3, 648-656.	2.6	18
35	Impact of biparametric prebiopsy prostate magnetic resonance imaging on the diagnostics of clinically significant prostate cancer in biopsy naïve men. <i>Scandinavian Journal of Urology</i> , 2020, 54, 7-13.	0.6	0
36	Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with 68Ga-PSMA-11 PET/MRI in men with treatment-naïve prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 665-673.	3.3	42

#	ARTICLE	IF	CITATIONS
37	Reply to Joshua S. Jue and Mahmoud Alameddine's Letter to the Editor re: Juha Knaapila, Ivan Jambor, Ileana Montoya Perez, et al. Prebiopsy IMPROD Biparametric Magnetic Resonance Imaging Combined with Prostate-Specific Antigen Density in the Diagnosis of Prostate Cancer: An External Validation Study. <i>Eur Urol Oncol</i> 2020;3:648-656. <i>European Urology Oncology</i> , 2020, 3, 711-712.	2.6	2
38	Qualitative and Quantitative Reporting of a Unique Biparametric MRI: Towards Biparametric MRI-Based Nomograms for Prediction of Prostate Biopsy Outcome in Men With a Clinical Suspicion of Prostate Cancer (IMPROD and MULTIMPROD Trials). <i>Journal of Magnetic Resonance Imaging</i> , 2020, 51, 1556-1567.	1.9	22
39	Vasectomy and the risk of prostate cancer in a Finnish nationwide population-based cohort. <i>Cancer Epidemiology</i> , 2020, 64, 101631.	0.8	5
40	Re: Antonio C. Westphalen, Charles E. McCulloch, Jordan M. Anaokar, et al. Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. <i>Radiology</i> 2020;296:76-84. <i>European Urology Oncology</i> , 2020, 3, 714-715.	2.6	1
41	Critical evaluation of the subcutaneous engraftments of hormone naïve primary prostate cancer. <i>Translational Andrology and Urology</i> , 2020, 9, 1120-1134.	0.6	3
42	FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment? <i>European Urology</i> , 2020, 78, 682-687.	0.9	57
43	Prediction of prostate cancer aggressiveness using 18F-Fluciclovine (FACBC) PET and multisequence multiparametric MRI. <i>Scientific Reports</i> , 2020, 10, 9407.	1.6	3
44	Familial aggregation of testicular cancer among early-onset cancer survivors. A prospective observational cohort data from Finland. <i>Cancer Epidemiology</i> , 2020, 69, 101807.	0.8	2
45	Acute and subacute prostate MRI findings after MRI-guided transurethral ultrasound ablation of prostate cancer. <i>Acta Radiologica</i> , 2020, 62, 028418512097693.	0.5	6
46	Palliative MRI-guided transurethral ultrasound ablation for symptomatic locally advanced prostate cancer. <i>Scandinavian Journal of Urology</i> , 2020, 54, 481-486.	0.6	7
47	Added value of systematic biopsy in men with a clinical suspicion of prostate cancer undergoing biparametric MRI-targeted biopsy: multi-institutional external validation study. <i>World Journal of Urology</i> , 2020, 39, 1879-1887.	1.2	15
48	Salvage Magnetic Resonance Imaging-guided Transurethral Ultrasound Ablation for Localized Radiorecurrent Prostate Cancer: 12-Month Functional and Oncological Results. <i>European Urology Open Science</i> , 2020, 22, 79-87.	0.2	16
49	Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RT-qPCR of KRT5, KRT20, and ERBB2 in Muscle-Invasive Bladder Cancer Treated by Adjuvant Chemotherapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7420.	1.8	2
50	Clinical markers of morbidity, mortality and survival in bladder cancer patients treated with radical cystectomy. A systematic review. <i>Scandinavian Journal of Urology</i> , 2020, 54, 267-276.	0.6	3
51	Survival and mortality of elderly men with localized prostate cancer managed with primary androgen deprivation therapy or by primary observation. <i>BMC Urology</i> , 2020, 20, 25.	0.6	0
52	Tournament leave-pair-out cross-validation for receiver operating characteristic analysis. <i>Statistical Methods in Medical Research</i> , 2019, 28, 2975-2991.	0.7	13
53	Urine cytology is a feasible tool for assessing erythematous bladder lesions after bacille Calmette-Guérin (BCG) treatment. <i>BJU International</i> , 2019, 123, 246-251.	1.3	4
54	Radiomics and machine learning of multisequence multiparametric prostate MRI: Towards improved non-invasive prostate cancer characterization. <i>PLoS ONE</i> , 2019, 14, e0217702.	1.1	76

#	ARTICLE	IF	CITATIONS
55	Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension. <i>European Urology</i> , 2019, 76, 586-595.	0.9	68
56	Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. <i>European Urology</i> , 2019, 76, 430-434.	0.9	31
57	Reply to Mengxin Lu, Yi Zhang, Yu Xiao's Letter to the Editor, re: Kimmo Kettunen, Peter J. Boström, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. <i>Eur Urol</i> 2019;76:430-434. <i>European Urology</i> , 2019, 76, e137-e138.	0.9	1
58	rs77559646 Is Associated With First-line Docetaxel Treatment Response in Metastatic Castration-resistant Prostate Cancer. <i>Anticancer Research</i> , 2019, 39, 5353-5359.	0.5	7
59	Correlation between 18F-1-amino-3-fluorocyclobutane-1-carboxylic acid (18F-fluciclovine) uptake and expression of alanine-serine-cysteine-transporter 2 (ASCT2) and L-type amino acid transporter 1 (LAT1) in primary prostate cancer. <i>EJNMMI Research</i> , 2019, 9, 50.	1.1	14
60	Histopathological evaluation of prostate specimens after thermal ablation may be confounded by the presence of thermally-fixed cells. <i>International Journal of Hyperthermia</i> , 2019, 36, 914-924.	1.1	6
61	Prediction of complication related death after radical cystectomy for bladder cancer with machine learning methodology. <i>Scandinavian Journal of Urology</i> , 2019, 53, 325-331.	0.6	16
62	Feasibility of MRI-guided transurethral ultrasound for lesion-targeted ablation of prostate cancer. <i>Scandinavian Journal of Urology</i> , 2019, 53, 295-302.	0.6	23
63	Clinical Utility of Mutant Antibody-Based Assays for Determination of Internally Cleaved and Intact Forms of Free Prostate-Specific Antigen. <i>journal of applied laboratory medicine</i> , The, 2019, 3, 1014-1021.	0.6	0
64	Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer: A prospective multi-institutional trial. <i>PLoS Medicine</i> , 2019, 16, e1002813.	3.9	43
65	SORLA regulates endosomal trafficking and oncogenic fitness of HER2. <i>Nature Communications</i> , 2019, 10, 2340.	5.8	49
66	IMPROD biparametric MRI in men with a clinical suspicion of prostate cancer (IMPROD Trial): Sensitivity for prostate cancer detection in correlation with whole-mount prostatectomy sections and implications for focal therapy. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 50, 1641-1650.	1.9	16
67	Adverse Events During Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2019, 5, 273-279.	0.2	9
68	Cell-type-specific CD73 expression is an independent prognostic factor in bladder cancer. <i>Carcinogenesis</i> , 2019, 40, 84-92.	1.3	27
69	Progress towards a Nordic standard for the investigation of hematuria: 2019. <i>Scandinavian Journal of Urology</i> , 2019, 53, 1-6.	0.6	14
70	Prevalence of Complications Leading to a Health Care Contact After Transrectal Prostate Biopsies: A Prospective, Controlled, Multicenter Study Based on a Selected Study Cohort. <i>European Urology Focus</i> , 2019, 5, 443-448.	1.6	16
71	Computerized histomorphometric features of glandular architecture predict risk of biochemical recurrence following radical prostatectomy: A multisite study. <i>Journal of Clinical Oncology</i> , 2019, 37, 5060-5060.	0.8	2
72	Time trends and occupational variation in the incidence of testicular cancer in the Nordic countries. <i>BJU International</i> , 2018, 122, 384-393.	1.3	21

#	ARTICLE	IF	CITATIONS
73	The composition of prostate core matrisome in vivo and in vitro unveiled by mass spectrometric analysis. <i>Prostate</i> , 2018, 78, 583-594.	1.2	11
74	Antibiotic susceptibility of intestinal <i>Escherichia coli</i> in men undergoing transrectal prostate biopsies: a prospective, registered, multicentre study. <i>BJU International</i> , 2018, 122, 203-210.	1.3	14
75	A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma. <i>European Urology Focus</i> , 2018, 4, 995-1001.	1.6	26
76	New prostate cancer grade grouping system predicts survival after radical prostatectomy. <i>Human Pathology</i> , 2018, 75, 159-166.	1.1	17
77	The impact of socioeconomic status on stage specific prostate cancer survival and mortality before and after introduction of PSA test in Finland. <i>International Journal of Cancer</i> , 2018, 142, 891-898.	2.3	10
78	Prospective evaluation of 18F-FACBC PET/CT and PET/MRI versus multiparametric MRI in intermediate- to high-risk prostate cancer patients (FLUCIPRO trial). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 355-364.	3.3	66
79	Neoadjuvant Chemotherapy Does Not Increase the Morbidity of Radical Cystectomy: A 10-year Retrospective Nationwide Study. <i>European Urology Oncology</i> , 2018, 1, 525-530.	2.6	23
80	ANO7 is associated with aggressive prostate cancer. <i>International Journal of Cancer</i> , 2018, 143, 2479-2487.	2.3	31
81	Intratumoral androgen levels are linked to TMPRSS2-ERG fusion in prostate cancer. <i>Endocrine-Related Cancer</i> , 2018, 25, 807-819.	1.6	16
82	¹¹ C-acetate PET/MRI in bladder cancer staging and treatment response evaluation to neoadjuvant chemotherapy: a prospective multicenter study (ACEBIB trial). <i>Cancer Imaging</i> , 2018, 18, 25.	1.2	22
83	Fitting methods for intravoxel incoherent motion imaging of prostate cancer on region of interest level: Repeatability and gleason score prediction. <i>Magnetic Resonance in Medicine</i> , 2017, 77, 1249-1264.	1.9	48
84	Non-muscle-invasive bladder cancer: a vision for the future. <i>Scandinavian Journal of Urology</i> , 2017, 51, 87-94.	0.6	33
85	Novel biparametric MRI and targeted biopsy improves risk stratification in men with a clinical suspicion of prostate cancer (IMPROD Trial). <i>Journal of Magnetic Resonance Imaging</i> , 2017, 46, 1089-1095.	1.9	75
86	Stage-specific mortality and survival trends of prostate cancer patients in Finland before and after introduction of PSA. <i>Acta Oncologica</i> , 2017, 56, 971-977.	0.8	11
87	Radiomic features for prostate cancer detection on MRI differ between the transition and peripheral zones: Preliminary findings from a multi-institutional study. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 46, 184-193.	1.9	114
88	Immunological tumor status may predict response to neoadjuvant chemotherapy and outcome after radical cystectomy in bladder cancer. <i>Scientific Reports</i> , 2017, 7, 12682.	1.6	16
89	Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. <i>Journal of Clinical Oncology</i> , 2017, 35, 2299-2305.	0.8	241
90	A propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic. <i>Journal of Clinical Oncology</i> , 2017, 35, e16003-e16003.	0.8	0

#	ARTICLE	IF	CITATIONS
91	Hypoxia Marker GLUT-1 (Glucose Transporter 1) is an Independent Prognostic Factor for Survival in Bladder Cancer Patients Treated with Radical Cystectomy. <i>Bladder Cancer</i> , 2016, 2, 101-109.	0.2	31
92	Benefit of Adjuvant Chemotherapy and Pelvic Lymph Node Dissection in pT3 and Node Positive Bladder Cancer Patients Treated with Radical Cystectomy. <i>Bladder Cancer</i> , 2016, 2, 263-272.	0.2	7
93	Patient-specific pharmacokinetic parameter estimation on dynamic contrast-enhanced MRI of prostate: Preliminary evaluation of a novel AIF-free estimation method. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 44, 1405-1414.	1.9	3
94	Relaxation along fictitious field, diffusion-weighted imaging, and T_2 mapping of prostate cancer: Prediction of cancer aggressiveness. <i>Magnetic Resonance in Medicine</i> , 2016, 75, 2130-2140.	1.9	15
95	Increased expression of fibroblast growth factor 13 in prostate cancer is associated with shortened time to biochemical recurrence after radical prostatectomy. <i>International Journal of Cancer</i> , 2016, 139, 140-152.	2.3	23
96	Diffusion weighted imaging of prostate cancer: Prediction of cancer using texture features from parametric maps of the monoexponential and kurtosis functions. , 2016, , .		6
97	Initiation of robot-assisted radical prostatectomies in Finland: Impact on centralization and quality of care. <i>Scandinavian Journal of Urology</i> , 2016, 50, 149-154.	0.6	16
98	Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon- α 2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study. <i>European Urology</i> , 2016, 70, 341-347.	0.9	23
99	Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy. <i>Modern Pathology</i> , 2016, 29, 1565-1574.	2.9	43
100	Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy. <i>Journal of Urology</i> , 2016, 196, 1627-1633.	0.2	36
101	Longitudinal modeling of ultrasensitive and traditional prostate-specific antigen and prediction of biochemical recurrence after radical prostatectomy. <i>Scientific Reports</i> , 2016, 6, 36161.	1.6	3
102	Stratification of aggressive prostate cancer from indolent disease—Prospective controlled trial utilizing expression of 11 genes in apparently benign tissue. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 255.e15-255.e22.	0.8	8
103	Global expression of AMACR transcripts predicts risk for prostate cancer—a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate. <i>BMC Urology</i> , 2016, 16, 10.	0.6	19
104	Rotating frame relaxation imaging of prostate cancer: Repeatability, cancer detection, and Gleason score prediction. <i>Magnetic Resonance in Medicine</i> , 2016, 75, 337-344.	1.9	16
105	Incidence, characteristics, and implications of thrombo-embolic events in patients with urothelial carcinoma of the bladder undergoing neoadjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 393-393.	0.8	1
106	Detection of prostate cancer with the $[^{68}\text{Ga}]$ -labeled bombesin antagonist RM2 in patients undergoing radical prostatectomy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 80-80.	0.8	4
107	Validation of Novel Biomarkers for Prostate Cancer Progression by the Combination of Bioinformatics, Clinical and Functional Studies. <i>PLoS ONE</i> , 2016, 11, e0155901.	1.1	43
108	Mathematical models for diffusion-weighted imaging of prostate cancer using b values up to 2000 s/mm^2 : Correlation with Gleason score and repeatability of region of interest analysis. <i>Magnetic Resonance in Medicine</i> , 2015, 74, 1116-1124.	1.9	53

#	ARTICLE	IF	CITATIONS
109	Evaluation of different mathematical models for diffusion-weighted imaging of normal prostate and prostate cancer using high b-values: A repeatability study. <i>Magnetic Resonance in Medicine</i> , 2015, 73, 1988-1998.	1.9	72
110	Tumor-Associated Macrophages Provide Significant Prognostic Information in Urothelial Bladder Cancer. <i>PLoS ONE</i> , 2015, 10, e0133552.	1.1	55
111	Role of ultrasensitive prostate-specific antigen in the follow-up of prostate cancer after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 16.e1-16.e7.	0.8	5
112	Erectile dysfunction cannot be used in primary screening of pre-diabetes. <i>Diabetes Research and Clinical Practice</i> , 2015, 108, e60-e62.	1.1	6
113	Genomic Predictors of Outcome in Prostate Cancer. <i>European Urology</i> , 2015, 68, 1033-1044.	0.9	166
114	Long-term Outcome of Patients with Frequently Recurrent Non-muscle-invasive Bladder Carcinoma Treated with One Perioperative Plus Four Weekly Instillations of Mitomycin C Followed by Monthly Bacillus Calmette-Guérin (BCG) or Alternating BCG and Interferon- β Instillations: Prospective Randomised FinnBladder-4 Study. <i>European Urology</i> , 2015, 68, 611-617.	0.9	27
115	Altered PCA3 and TMPRSS2-ERG expression in histologically benign regions of cancerous prostates: a systematic, quantitative mRNA analysis in five prostates. <i>BMC Urology</i> , 2015, 15, 88.	0.6	6
116	Diffusion-weighted imaging of prostate cancer: effect of b-value distribution on repeatability and cancer characterization. <i>Magnetic Resonance Imaging</i> , 2015, 33, 1212-1218.	1.0	23
117	Reply from Authors re: Robert S. Svatek. Long-term Outcomes of the FinnBladder-4 Study. <i>Eur Urol</i> 2015;68:618-619. <i>European Urology</i> , 2015, 68, 619-620.	0.9	1
118	Differential Predictive Roles of A- and B-Type Nuclear Lamins in Prostate Cancer Progression. <i>PLoS ONE</i> , 2015, 10, e0140671.	1.1	39
119	Bulbourethral gland adenocarcinoma in a 25-year-old man without comorbidities: Radical resection of proximal urethrae with Mitrofanoff-type appendicovesicostomy. <i>Scandinavian Journal of Urology</i> , 2014, 48, 405-409.	0.6	3
120	High-Intensity Physical Activity, Stable Relationship, and High Education Level Associate with Decreasing Risk of Erectile Dysfunction in 1,000 Apparently Healthy Cardiovascular Risk Subjects. <i>Journal of Sexual Medicine</i> , 2014, 11, 2277-2284.	0.3	15
121	European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media. <i>European Urology</i> , 2014, 66, 628-632.	0.9	72
122	FGFR3 mutations, but not FGFR3 expression and FGFR3 copy-number variations, are associated with favourable non-muscle invasive bladder cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 465, 207-213.	1.4	23
123	Patients with Lynch Syndrome Mismatch Repair Gene Mutations Are at Higher Risk for Not Only Upper Tract Urothelial Cancer but Also Bladder Cancer. <i>European Urology</i> , 2013, 63, 379-385.	0.9	85
124	Upper urinary tract and urethral recurrences following radical cystectomy: review of risk factors and outcomes between centres with different follow-up protocols. <i>World Journal of Urology</i> , 2013, 31, 161-167.	1.2	28
125	Seminal vesicles and urinary bladder as sites of aromatization of androgens in men, evidenced by a CYP19A1-driven luciferase reporter mouse and human tissue specimens. <i>FASEB Journal</i> , 2013, 27, 1342-1350.	0.2	7
126	Lack of Decorin Expression by Human Bladder Cancer Cells Offers New Tools in the Therapy of Urothelial Malignancies. <i>PLoS ONE</i> , 2013, 8, e76190.	1.1	30

#	ARTICLE	IF	CITATIONS
127	The <i>FGFR3</i> Mutation is Related to Favorable pT1 Bladder Cancer. <i>Journal of Urology</i> , 2012, 187, 310-314.	0.2	85
128	External Validation of a Biomarker Based Pre-Cystectomy Algorithm to Predict Nonorgan Confined Urothelial Cancers. <i>Journal of Urology</i> , 2012, 187, 840-844.	0.2	7
129	Sex differences in bladder cancer outcomes among smokers with advanced bladder cancer. <i>BJU International</i> , 2012, 109, 70-76.	1.3	22
130	A New and Highly Prognostic System to Discern T1 Bladder Cancer Substage. <i>European Urology</i> , 2012, 61, 378-384.	0.9	144
131	Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome. <i>BJU International</i> , 2012, 110, 804-811.	1.3	96
132	Prognostic value of molecular markers, substage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer. <i>BJU International</i> , 2012, 110, 1169-1176.	1.3	53
133	Does patient age affect survival after radical cystectomy?. <i>BJU International</i> , 2012, 110, E486-93.	1.3	28
134	Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. <i>BJU International</i> , 2011, 108, 24-30.	1.3	111
135	Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort. <i>BJU International</i> , 2011, 108, E237-E244.	1.3	62
136	Point-of-care clinical documentation: assessment of a bladder cancer informatics tool (<i>eCancerCare^{Bladder}</i>): a randomized controlled study of efficacy, efficiency and user friendliness compared with standard electronic medical records. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2011, 18, 835-841.	2.2	10
137	Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin. <i>Urology Annals</i> , 2011, 3, 119.	0.3	23
138	Optimal timing of radical cystectomy in T1 high-grade bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1891-1902.	1.1	8
139	Imaging renal cell carcinoma with ultrasonography, CT and MRI. <i>Nature Reviews Urology</i> , 2010, 7, 311-325.	1.9	49
140	Staging and Staging Errors in Bladder Cancer. <i>European Urology Supplements</i> , 2010, 9, 2-9.	0.1	53
141	Nutraceuticals and prostate cancer prevention: a current review. <i>Nature Reviews Urology</i> , 2010, 7, 21-30.	1.9	101
142	Twenty-year experience of radical cystectomy for bladder cancer in a medium-volume centre. <i>Scandinavian Journal of Urology and Nephrology</i> , 2009, 43, 357-364.	1.4	16
143	Risk factors for mortality and morbidity related to radical cystectomy. <i>BJU International</i> , 2009, 103, 191-196.	1.3	133
144	Protodynamic therapy for bladder cancer: <i>in vitro</i> results of a novel treatment concept. <i>BJU International</i> , 2009, 104, 1233-1238.	1.3	13

#	ARTICLE	IF	CITATIONS
145	Bladder Cancer After Radiotherapy for Prostate Cancer: Detailed Analysis of Pathological Features and Outcome After Radical Cystectomy. <i>Journal of Urology</i> , 2008, 179, 91-95.	0.2	42
146	Upper Urinary Tract Cancer—Challenges for the Urologist. <i>Journal of Urology</i> , 2007, 178, 12-13.	0.2	3
147	Secondary Cancer After Radiotherapy for Prostate Cancer: Should We Be More Aware of the Risk?. <i>European Urology</i> , 2007, 52, 973-982.	0.9	79
148	Expression of cyclooxygenase-1 and -2 in urinary bladder carcinomas in vivo and in vitro and prostaglandin E2 synthesis in cultured bladder cancer cells. <i>Pathology</i> , 2001, 33, 469-474.	0.3	33
149	Interferon- γ inhibits cyclooxygenase-1 and stimulates cyclooxygenase-2 expression in bladder cancer cells in vitro. <i>Urological Research</i> , 2001, 29, 20-24.	1.5	21
150	Expression of collagenase-3 (matrix metalloproteinase-13) in transitional-cell carcinoma of the urinary bladder. <i>International Journal of Cancer</i> , 2000, 88, 417-423.	2.3	58
151	Urinary Bladder Transitional Cell Carcinogenesis Is Associated with Down-Regulation of NF1 Tumor Suppressor Gene in Vivo and in Vitro. <i>American Journal of Pathology</i> , 1999, 154, 755-765.	1.9	38